Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

Journal of Virology

Volumn 72, Issue 11, 1998, Pages 9092-9100

  Richmond, J F L ^a   Lu, S ^a   Santoro, J C ^a   Weng, J ^a   Hu, Shiu Lok ^b   Montefiori, D C ^c   Robinson, H L ^a,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VACCINATION; VIRUS ENVELOPE;

EID: 0031657986     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.11.9092-9100.1998     Document Type: Article

References (66)

1. Barnett, S. W., S. Rajasekar, H. Legg, B. Doe, D. H. Fuller, J. R. Haynes, C. M. Walker, and K. S. Steimer. 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15:869-873.
2. Binley, J. M., H. Arshad, T. R. Fouts, and J. P. Moore. 1997. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13:1007-1015.
3. Binley, J. M., P. J. Klasse, Y. Cao, I. Jones, M. Markowitz, D. D. Ho, and J. P. Moore. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71:2799-2809.
4. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:526-532.
5. Boyle, C. M., M. Morin, R. G. Webster, and H. L. Robinson. 1996. Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein. J. Virol. 70:9074-9078.
6. Broder, C. C., P. L. Earl, D. Long, S. T. Abdeon, B. Moss, and R. W. Doms. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure oligomeric-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91:11699-11703.
7. Charoenvit, Y., M. Sedegah, L. F. Yuan, M. Gross, C. Cole, R. Bechara, M. F. Leef, F. A. Robey, G. H. Lowell, R. L. Beaudoin, and S. L. Hoffman. 1990. Active and passive immunization against Plasmodium yoelii sporozoites. Bull. W. H. O. 68(Suppl.):26-32.
8. Clements, J. E., R. C. Montelaro, M. C. Zink, A. M. Amedee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, R. P. Bohm, and M. Murphey-Corb. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737-2744.
9. Cole, K. S., J. L. Rowles, B. A. Jagerski, M. Murphey-Corb, T. Unangst, J. E. Clements, J. Robinson, M. S. Wyand, R. C. Derosiers, and R. C. Montelaro. 1997. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 71:5069-5079.
10. Dolin, R. 1995. Human studies in the development of human immunodeficiency virus vaccines. J. Infect. Dis. 172:1175-1183.
11. Earl, P. L., S. Koenig, and B. Moss. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31-41.
12. Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody responses. J. Virol. 68:3015-3026.
13. gag precursor protein. J. Virol. 70:6547-6556.
14. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
15. Fuller, D. H., and J. R. Haynes. 1994. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 10:1433-1441.
16. Fuller, D. H., M. Murphey-Corb, J. Clements, S. Barnett, and J. R. Haynes. 1996. Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J. Med. Primatol. 25:236-241.
17. Fuller, D. H., M. M. Corb, S. Barnett, K. Steimer, and J. R. Haynes. 1997. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 15:924-925.
18. Girard, M., E. van der Ryst, F. Barré-Sinoussi, P. Nara, J. Tartaglia, E. Paoletti, C. Blondeau, M. Jennings, F. Verrier, B. Meignier, and P. N. Fultz. 1997. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology 232:98-104.
19. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, and G. E. Smith. 1993. Augmentation of human immunodeficiency virus type 1 and neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167:533-537.
20. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, L. Corey, G. J. Gorse, D. H. Schwartz, M. C. Keefer, J. McElrath, D. P. Bolognesi, D. M. Stablein, J. R. Esterlitz, S. L. Hu, G. Smith, and P. F. Wright. 1994. Determinants of antibody response after rgp160 boosting in vaccinia-naive volunteers primed with gp160 recombinant vaccinia. J. Infect. Dis. 170:782-786.
21. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331-1339.
22. Gray, B. M., and D. R. Shaw. 1993. Artifacts with the thiocyanate elution method for estimating relative antibody avidity. J. Immunol. Methods 157: 269-271.
23. Hallenberger, S., S. P. Tucker, R. J. Owens, H. B. Bernstein, and R. W. Compans. 1993. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology 193:510-514.
24. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:3840-3852.
25. Hanson, C. V. 1994. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses 10:645-648.
26. Hu, S.-L., J. Klaniecki, T. Dykers, P. Sridhar, and B. M. Travis. 1991. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 envelope glycoproteins and boosted with gp160. AIDS Res. Hum. Retroviruses 7:615-620.
27. Hu, S.-L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
28. Kangro, H. O., S. Manzoor, and D. R. Harper. 1991. Antibody avidity following varicella-zoster virus infections. J. Med. Virol. 33:100-103.
29. Katz, E., and B. Moss. 1997. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Res. Hum. Retroviruses 13:1497-1500.
30. Klaniecki, J., T. Dykers, B. Travis, R. Schmitt, M. Wain, A. Watson, P. Sridhar, J. McClure, B. Morein, J. T. Ulrich, and S.-L. Hu. 1991. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res. Hum. Retroviruses 7:791-798.
31. Leinikki, P. O., I. Shekarchi, P. Dorsett, and J. L. Sever. 1978. Enzyme-linked immunosorbent assay determination of specific rubella antibody levels in micrograms of immunoglobulin G per milliliter of serum in clinical samples. J. Clin. Microbiol. 8:419-423.
32. Leonard, C. K., M. W. Spellman, L. Ruddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
33. Letvin, N. L., D. C. Montefiori, Y. Yasutomi, H. C. Perry, M. E. Davies, C. Lekutis, M. Alroy, D. C. Freed, C. I. Lord, L. K. Handt, M. A. Liu, and J. W. Shiver. 1997. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 94:9378-9383.
34. Lu, S., J. C. Santoro, D. H. Fuller, J. E. Haynes, and H. L. Robinson. 1995. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209:147-154.
35. Lu, S., J. Arthos, D. C. Montefiori, Y. Yasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, J. R. Haynes, N. L. Letvin, M. Wyand, and H. L. Robinson. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3973-3991.
36. Lu, S., R. Wyatt, J. F. L. Richmond, F. Mustafa, S. Wang, J. Weng, D. C. Montefiori, J. Sodroski, and H. L. Robinson. 1998. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14:151-155.
37. Luxton, R. W., and E. J. Thompson. 1990. Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis. J. Immunol. Methods 131:277-282.
38. MacLennan, I. C. M. 1994. Germinal centers. Annu. Rev. Immunol. 12:117-139.
39. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Reefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, D. S. Burke, and the National Institute of Allergy and Infectious Disease AIDS Vaccine Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
40. Michel, M.-L., H. L. Davis, M. Schleef, M. Mancini, P. Tiollais, and R. G. Whalen. 1995. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA 92:5307-5311.
41. Montefiori, D. C., W. E. Robinson, Jr., S. S. Schuffman, and W. M. Mitchell. 1988. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:231-237.
42. Montefiori, D. C., B. S. Graham, J. Zhou, J. Zhou, R. A. Bucco, D. H. Schwartz, L. A. Cavacini, M. R. Posner, and the NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Investig. 92:840-847.
43. Montefiori, D. C., G. Pantaleo, L. M. Fink, J. T. Zhou, J. Y. Zhou, M. Bilska, G. D. Miralles, and A. S. Fauci. 1996. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:60-67.
44. Moog, C., H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
45. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 1995 9:S117-S136.
46. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
47. Mustafa, F., J. F. L. Richmond, R. Fernandez-Larsson, S. Lu, R. Fredricksson, E. M. Fenyö, M. O'Connell, E. Johnson, J. Weng, J. C. Santoro, and H. L. Robinson. 1997. HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology 229:269-278.
48. Myers, G., S. Wain-Hobson, L. E. Henderson, B. Korber, K.-T. Jeang, and G. N. Pavlakis. 1994. Human retroviruses and AIDS 1994. Los Alamos Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N. Mex.
49. Pincus, S. H., K. G. Messer, D. H. Schwartz, G. K. Lewis, B. S. Graham, W. A. Blatter, and G. Fisher. 1993. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Investig. 91:1981-1996.
50. Pincus, S. H., K. G. Messer, R. Cole, R. Ireland, T. C. VanCott, A. Pinter, D. H. Schwartz, B. S. Graham, and G. J. Gorse. 1997. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. 158:3511-3520.
51. Richmond, J. F. L., F. Mustafa, S. Lu, J. C. Santoro, J. Weng, M. O'Connell, E. M. Fenyö, J. L. Hurwitz, D. C. Montefiori, and H. L. Robinson. 1997. Screening HIV-1 glycoproteins for the ability to elicit neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 230:265-274.
52. Robinson, H. L., D. M. Feltquate, and M. J. Morin. 1995. DNA vaccines: a new approach to immunization, p. 69-75. In F. Brown, R. Chancock, H. Ginsberg, and E. Norrby, (ed.), Vaccines 95. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
53. Robinson, H. L. 1997. DNA vaccines for immunodeficiency viruses. AIDS 1997 11(Suppl. A):S109-S119.
54. Robinson, J. E., D. Holton, J. Lui, H. McMurdo, A. Murciano, and R. Gohd. 1990. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immunol. Methods 132:63-71.
55. Rowell, J. F., P. E. Stanhope, and R. F. Siliciano. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. J. Immunol. 155:473-488.
56. Salmon-Céron, D., J. L. Excler, D. Sicard, P. Blanche, L. Finkielstzjen, J. C. Gluckman, B. Autran, T. J. Matthews, B. Meignier, M. P. Kieny, C. Valentin, P. Gonnet, I. Diaz, H. Salomon, G. Pialoux, G. Gonzalez-Canali, S. Plotkin, and the Agis Group and L'Agence Nationale de Recherche sur le SIDA. 1995. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res. Hum. Retroviruses 11:1479-1486.
57. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
58. Shiver, J. W., M.-E. Davies, Y. Yasutomi, H. C. Perry, D. C. Freed, N. L. Letvin, and M. A. Liu. 1997. Anti-HIV Env immunities elicited by nucleic acid vaccines. Vaccine 15:884-887.
59. Tew, J. G., R. M. DiLosa, G. F. Burton, M. H. Kosco, L. I. Kupp, A. Masuda, and A. K. Szakal. 1992. Germinal centers and antibody production in bone marrow. Immunol. Rev. 126:99-112.
60. VanCott, T. C., F. R. Bethke, D. S. Burke, R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
61. VanCott, T. C., V. R. Polonis, L. D. Loomis, N. L. Micheal, P. L. Nara, and D. L. Birx. 1995. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 11:1379-1391.
62. VanCott, T. C., J. R. Mascola, R. W. Kaminski, V. Kalyanaraman, P. L. Hallberg, P. R. Burnett, J. T. Ulrich, D. J. Rechtman, and D. L. Birx. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330.
63. Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, Y. Refaeli, A. Sato, J. Boyer, W. V. Williams, and D. B. Weiner. 1993. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:4156-4160.
64. Wang, B., J. Boyer, V. Srikantan, L. Coney, R. Carrano, C. Phan, M. Merva, K. Dang, M. Agadjanyan, L. Gilbert, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1993. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol. 12:799-805.
65. Ward, K. N., W. Dhaliwal, K. L. Ashworth, E. J. Clutterbuck, and C. G. Teo. 1994. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J. Med. Virol. 43:367-372.
66. Yang, K., F. Mustafa, A. Valsamakis, J. C. Santoro, D. E. Griffen, and H. L. Robinson. 1997. Early studies on DNA-based immunizations for measles virus. Vaccine 15:888-891.